Atherosclerosis Drugs Market Report

The global atherosclerosis drugs market's key players actively engage in research and development in order to launch novel atherosclerosis drugs. Due to plaque development, the frequency and incidence of cardiovascular issues is increasing, raising the demand for novel therapeutic options. E-selectin-targeting polymer is a new polymer developed by Ben-Gurion University (BGU) and the Sheba Medical Centre in June 2022. It is a revolutionary treatment for atherosclerosis that reduces the risk of stroke, ischemia, arterial thrombosis and myocardial infarction by decreasing and preventing plaque formation. Protein Convertase Subtilisin/Kexin type 9 (PCSK 9) statin therapy reduces low-density lipoprotein cholesterol levels, lowering the risk of coronary atherosclerotic plaque formation. New therapies for atherosclerosis are expected to drive the growth of the global market for atherosclerosis drugs.

Additionally, field of cardiology is continuously evolving and recent developments in the field of interventional cardiology have dramatically changed the plan of treatment in atherosclerosis. Furthermore, Interventional cardiology involves the use of a catheter, a small flexible tube, to treat damaged or weakened vessels, narrowed arteries, or other affected areas of the heart without surgery. An interventional cardiologist receives extra education and training for one to two years to diagnose and treat cardiovascular disease, congenital, and structural heart conditions using catheter-based procedures like angioplasty and stenting. Technological advancements and development of novel approaches pose great opportunities for atherosclerosis drug market.

The market's expansion will be restricted by a lack of awareness about the causes, effects, and treatments of atherosclerosis. However, the rush to approve and introduce pharmaceuticals for treating patients has resulted in rapid drug approvals without adequate monitoring and a lack of sufficient evidence proving the treatments' effectiveness. Rapid medicine approval has resulted in product recalls, which harms market participants' brand image and negatively impacts consumers. As a result of the rising number of product recalls, consumers have become increasingly concerned about the efficacy of the medications, resulting in decreasing demand. As a result, product recalls will hinder market growth.

Moreover, current medications for atherosclerosis are successful in controlling the condition, but they might not be able to stop the advancement of the disease or avoid issues for every individual. This limitation emphasizes the importance of continuous research to create better treatments. New treatment methods are being developed to target new pathways in disease processes, improve treatment results, and maybe even provide personalized care based on genetic and metabolic characteristics. These developments aim to enhance the effectiveness of managing atherosclerosis, reduce cardiovascular event risks, and improve the quality of life for those with this common chronic disease.

It is essential to make progress in the atherosclerosis drugs market in order to overcome existing challenges with effectiveness, side effects, and patient compliance. New treatments focusing on inflammation, individualized medicine methods using genetic analysis, and biological substances present opportunities for significant advancements. Improving treatment choices to have better results, fewer side effects, and superior patient outcomes will be crucial to address the increasing worldwide impact of cardiovascular diseases linked to atherosclerosis. For instance, in April 2024, Novartis today announced new data demonstrating the early addition of twice-yearly Leqvio (inclisiran) to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting significantly reduced low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), including those with a history of an ASCVD-related event, who could not reach their goal on statin therapy alone1. The late-breaking data were presented at the 2024 American College of Cardiology's Annual Scientific Session & Expo and simultaneously published in the Journal of the American College of Cardiology. In Addition, in April 2024, Roche announced that the Tina-quant lipoprotein Lp(a) RxDx assay has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) to identify patients who may benefit from innovative Lp(a)-lowering therapy currently in development.

North America is anticipated to dominate the global market throughout the forecast period. The presence of major firms, the high prevalence of heart diseases and atherosclerosis, and developed healthcare infrastructure are some of the main factors responsible for the market's large share. The centre for diseses control (CDC) estimates that around 86 million U.S. people aged 20 and older had total cholesterol levels more than 200 mg/dL. In the United States, about 25mMillion individuals have total cholesterol levels exceeding 240 mg/dL. Approximately 7% of children and adolescents aged 6 to 19 in the United States have high total cholesterol. Beneficial government efforts and an increase in the number of research collaborations are also anticipated to fuel market expansion. Due to favourable healthcare rules and regulations, a large number of patients and a developed healthcare sector, the United States has the largest share in this region. As a result, the aforementioned factors are likely to drive market growth in the region.